CCCC insider transactions
C4 Therapeutics Inc. (CCCC) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for CCCC
- Director Anderson Kenneth Carl exercised 1,070 shares at a strike of $2.11, increasing direct ownership by 2% to 69,300 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Anderson Kenneth Carl4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Grogan Donna Roy4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Business Officer Boyle Scott N was granted 200,000 shares, converted options into 25,950 shares and covered exercise/tax liability with 9,004 shares, increasing direct ownership by 177% to 298,801 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Scientific Officer Mahaney Paige was granted 240,000 shares, converted options into 7,050 shares and covered exercise/tax liability with 2,446 shares, increasing direct ownership by 239% to 336,910 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- President & CEO Hirsch Andrew was granted 700,000 shares, converted options into 102,125 shares and covered exercise/tax liability with 48,211 shares, increasing direct ownership by 154% to 1,074,934 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief People Officer Schick Kelly converted options into 25,950 shares, covered exercise/tax liability with 9,004 shares and was granted 200,000 shares, increasing direct ownership by 175% to 299,881 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Medical Officer Reyno Leonard was granted 240,000 shares, converted options into 30,950 shares and covered exercise/tax liability with 16,579 shares, increasing direct ownership by 143% to 379,803 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Accounting Officer Mossler Mark was granted 56,980 shares, converted options into 9,420 shares and covered exercise/tax liability with 3,268 shares, increasing direct ownership by 295% to 71,916 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Financial Officer Adams Kendra was granted 240,000 shares, converted options into 34,700 shares and covered exercise/tax liability with 17,244 shares, increasing direct ownership by 137% to 385,098 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Medical Officer Reyno Leonard sold $22,200 worth of shares (10,000 units at $2.22), decreasing direct ownership by 6% to 156,382 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Anderson Kenneth Carl was granted 5,958 shares, increasing direct ownership by 4% to 146,532 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Grogan Donna Roy was granted 7,513 shares, increasing direct ownership by 13% to 66,142 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Scientific Officer Mahaney Paige converted options into 19,200 shares and covered exercise/tax liability with 5,644 shares, increasing direct ownership by 16% to 99,356 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Anderson Kenneth Carl was granted 5,349 shares, increasing direct ownership by 4% to 140,574 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Grogan Donna Roy was granted 6,740 shares, increasing direct ownership by 13% to 58,629 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Financial Officer Adams Kendra converted options into 6,250 shares and covered exercise/tax liability with 2,775 shares, increasing direct ownership by 2% to 162,342 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Amendment: Chief Medical Officer Reyno Leonard converted options into 15,325 shares and covered exercise/tax liability with 7,382 shares, increasing direct ownership by 5% to 166,382 units (SEC Form 4)4/A - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Medical Officer Reyno Leonard covered exercise/tax liability with 7,382 shares, decreasing direct ownership by 4% to 166,382 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Anderson Kenneth Carl was granted 7,616 shares, increasing direct ownership by 6% to 135,225 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Grogan Donna Roy was granted 9,609 shares, increasing direct ownership by 23% to 51,889 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Koppikar Utpal4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Hughes Owen4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Fawell Stephen4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Anderson Kenneth Carl4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Bessen Laura4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Cooper Ronald Harold Wilfred4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Grogan Donna Roy4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Hoerter Steven L.4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Grogan Donna Roy was granted 9,581 shares, increasing direct ownership by 29% to 42,280 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Anderson Kenneth Carl was granted 7,841 shares, increasing direct ownership by 7% to 127,609 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- President & CEO Hirsch Andrew covered exercise/tax liability with 22,217 shares and was granted 223,500 shares, increasing direct ownership by 91% to 423,145 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Legal Officer Siegel Jolie covered exercise/tax liability with 5,049 shares and was granted 56,500 shares, increasing direct ownership by 91% to 107,939 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Business Officer Boyle Scott N covered exercise/tax liability with 4,103 shares, was granted 56,500 shares and sold $3,651 worth of shares (1,159 units at $3.15), increasing direct ownership by 91% to 107,805 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Accounting Officer Mossler Mark covered exercise/tax liability with 1,586 shares, decreasing direct ownership by 8% to 18,204 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief People Officer Schick Kelly was granted 56,500 shares and covered exercise/tax liability with 4,103 shares, increasing direct ownership by 93% to 108,885 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Financial Officer Adams Kendra covered exercise/tax liability with 6,422 shares and was granted 87,100 shares, increasing direct ownership by 96% to 165,117 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Scientific Officer Mahaney Paige was granted 28,200 shares, increasing direct ownership by 37% to 105,000 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Medical Officer Reyno Leonard was granted 87,100 shares and covered exercise/tax liability with 5,145 shares, increasing direct ownership by 89% to 173,764 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Hoerter Steven L.4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 3 filed by new insider Hoerter Steven L.3 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Legal Officer Siegel Jolie converted options into 3,750 shares and covered exercise/tax liability with 1,102 shares, increasing direct ownership by 5% to 56,488 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Business Officer Boyle Scott N converted options into 3,750 shares and covered exercise/tax liability with 1,102 shares, increasing direct ownership by 5% to 56,567 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief People Officer Schick Kelly converted options into 3,750 shares and covered exercise/tax liability with 1,102 shares, increasing direct ownership by 5% to 56,488 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Financial Officer Adams Kendra converted options into 3,750 shares and covered exercise/tax liability with 1,102 shares, increasing direct ownership by 3% to 84,439 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- President & CEO Hirsch Andrew converted options into 12,500 shares and covered exercise/tax liability with 5,550 shares, increasing direct ownership by 3% to 221,862 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Scientific Officer Mahaney Paige was granted 76,800 shares (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 3 filed by new insider Mahaney Paige3 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Anderson Kenneth Carl was granted 2,023 shares, increasing direct ownership by 2% to 116,694 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Director Grogan Donna Roy was granted 2,474 shares, increasing direct ownership by 9% to 28,942 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Financial Officer Adams Kendra covered exercise/tax liability with 1,837 shares, decreasing direct ownership by 2% to 81,791 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- President & CEO Hirsch Andrew converted options into 7,500 shares and covered exercise/tax liability with 3,329 shares, increasing direct ownership by 2% to 214,912 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Business Officer Boyle Scott N converted options into 2,250 shares and covered exercise/tax liability with 661 shares, increasing direct ownership by 3% to 53,919 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Financial Officer Adams Kendra converted options into 2,250 shares and covered exercise/tax liability with 661 shares, increasing direct ownership by 2% to 83,628 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Scientific Officer Fisher Stewart converted options into 2,250 shares and covered exercise/tax liability with 661 shares, increasing direct ownership by 1% to 130,710 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief People Officer Schick Kelly converted options into 2,250 shares and covered exercise/tax liability with 661 shares, increasing direct ownership by 3% to 53,840 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Legal Officer Siegel Jolie converted options into 2,250 shares and covered exercise/tax liability with 661 shares, increasing direct ownership by 3% to 53,840 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 4 filed by Director Fawell Stephen4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SEC Form 3 filed by new insider Fawell Stephen3 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- Chief Medical Officer Reyno Leonard covered exercise/tax liability with 6,191 shares, decreasing direct ownership by 6% to 91,809 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)